• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PEAK ROCK CAPITAL AFFILIATE SELLS PARAGON HEALTHCARE, INC. TO ELEVANCE HEALTH

    1/5/24 8:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email

    Paragon doubles revenues and increases the number of infusion centers by 400% during Peak Rock's ownership

    AUSTIN, Texas, Jan. 5, 2024 /PRNewswire/ -- An affiliate of Peak Rock Capital ("Peak Rock"), a leading middle-market private investment firm, announced today it has signed a definitive agreement for the sale of Paragon Healthcare, Inc. ("Paragon" or the "Company") to Elevance Health (NYSE:ELV).

    Paragon is a leading provider of ambulatory and home infusion services as well as specialty pharmacy services. The Company provides comprehensive, high quality infusion services to patients with chronic health conditions and those in need of post-acute care. Headquartered in Plano, Texas, with more than 70 infusion and pharmacy locations in 12 states, the Company has built an excellent reputation in the industry for its service to patients across lower-cost settings of care, including infusion centers and patients' homes.

    Since acquiring Paragon from its founders, Peak Rock supported the Company's strategic growth and operational initiatives. This included a significant expansion of the Company's ambulatory infusion center and pharmacy footprint, creating hundreds of jobs and expanding access to infusion care across multiple states. The Company also invested heavily in additional corporate infrastructure, including new team members, information technology systems, and enhanced operational capabilities. Paragon more than doubled revenue and increased the number of infusion centers by more than 400% during Peak Rock's ownership.

    Spencer Moore, Managing Director of Peak Rock, said, "Working with the team at Paragon has been a tremendous experience.  By supporting the Company with strategic and operational resources, Paragon has substantially grown its infusion footprint, patient-treatment capabilities, and organizational talent. These investments have enabled the business to support a rapidly growing patient-base, while helping to lower the cost of healthcare."

    Anthony Mollica, Chief Executive Officer of Paragon, added, "Peak Rock has been an invaluable partner to Paragon and has played a critical role in supporting our ambitious growth plans through investments in the Company's capabilities and people. We are excited to join Elevance Health and look forward to continuing to support our patients with high quality infusion care. In particular, I would like to thank the entire Paragon organization, without whom we could not have achieved our success to date."

    Anthony DiSimone, Chief Executive Officer of Peak Rock, said, "This transaction is another great example of Peak Rock's expertise in providing resources and strategic guidance to support the rapid growth and development of family and founder-owned businesses. We look forward to partnering with additional leading healthcare businesses that can benefit from Peak Rock's capabilities to achieve transformational outcomes."

    Jefferies LLC acted as the financial advisor and Kirkland & Ellis LLP acted as the legal advisor to the Company on the transaction.

    ABOUT PARAGON HEALTHCARE, INC.

    Founded in 2002, Paragon Healthcare, Inc. is a leading provider of infusion services to patients through its network of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. The Company provides high quality, convenient, comfortable, and lower cost care to patients with chronic and acute conditions. Paragon is based in Plano, Texas. For more information visit www.paragonhealthcare.com.

    ABOUT PEAK ROCK CAPITAL

    Peak Rock Capital is a leading middle-market private investment firm that makes equity and debt investments in companies in North America and Europe. Peak Rock's equity investment platform focuses on opportunities where it can support senior management to drive rapid growth and performance improvement, with expertise in corporate carve-outs and partnering with families and founders seeking first-time institutional capital. Peak Rock's credit platform invests across capital structures, with a broad mandate to provide flexible, tailored capital solutions to middle-market and growth-oriented businesses. Peak Rock's real estate platform makes equity and debt investments in small to mid-sized real estate assets in attractive, growing geographies. For further information about Peak Rock Capital, please visit www.peakrockcapital.com

    Media Contact:

    Daniel Yunger

    Kekst CNC

    (212) 521-4800

    daniel.yunger@kekstcnc.com

     

    Cision View original content:https://www.prnewswire.com/news-releases/peak-rock-capital-affiliate-sells-paragon-healthcare-inc-to-elevance-health-302026739.html

    SOURCE Peak Rock Capital LLC

    Get the next $ELV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    2/3/2026$358.00Outperform → Sector Perform
    RBC Capital Mkts
    1/8/2026$425.00Peer Perform → Outperform
    Wolfe Research
    12/19/2025$320.00Buy → Hold
    Deutsche Bank
    10/14/2025Neutral
    Goldman
    7/21/2025Buy → Hold
    Argus
    7/18/2025$310.00Outperform → Market Perform
    Leerink Partners
    4/15/2025$529.00Outperform → Neutral
    Robert W. Baird
    3/17/2025$450.00Hold → Buy
    Argus
    More analyst ratings

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elevance Health downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Elevance Health from Outperform to Sector Perform and set a new price target of $358.00

    2/3/26 6:49:01 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Elevance Health from Peer Perform to Outperform and set a new price target of $425.00

    1/8/26 8:09:47 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Elevance Health from Buy to Hold and set a new price target of $320.00

    12/19/25 8:44:26 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elevance Health and National Diaper Bank Network Launch National Pilot to Address Diaper Affordability and Improve Family Health

    National partnership will serve up to 9,000 families across 10 communities while reducing financial strain and studying impacts on maternal and child health Elevance Health (NYSE:ELV) and the National Diaper Bank Network (NDBN) today announced a new national pilot program designed to expand access to diapers for families with infants and young children, helping reduce financial strain while generating evidence on how meeting basic material needs can improve maternal and child health outcomes. The 12-month pilot program will provide free diapers to up to 75 families per month at 10 Welcome Rooms operated by Elevance Health affiliated Medicaid health plans in communities across the countr

    3/3/26 10:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization

    Elevance Health, Inc. (NYSE:ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company's strategy to lower the cost of care. Carelon's operating priorities and client commitments remain unchanged. Felicia Norwood, Executive Vice President and Chief Health Benef

    2/26/26 3:02:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Reports Fourth Quarter and Full Year 2025 Results; Sets Full Year 2026 Outlook

    4Q 2025 operating revenue of $49.3 billion; FY 2025 of $197.6 billion 4Q 2025 diluted EPS1 of $2.47; adjusted diluted EPS2 of $3.33 FY 2025 diluted EPS1 of $25.21; adjusted diluted EPS2 of $30.29 Projected FY 2026 GAAP diluted EPS1 to be at least $22.30 Projected FY 2026 adjusted diluted EPS2 to be at least $25.50 Returned $4.1 billion of capital to shareholders in 2025 Reaffirming long-term earnings algorithm; recalibrating segment margin targets Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2025 results. "Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined execution in a dynamic environment. As

    1/28/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    SEC Filings

    View All

    SEC Form DEFA14A filed by Elevance Health Inc.

    DEFA14A - Elevance Health, Inc. (0001156039) (Filer)

    3/27/26 4:21:47 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by Elevance Health Inc.

    DEF 14A - Elevance Health, Inc. (0001156039) (Filer)

    3/27/26 4:21:11 PM ET
    $ELV
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Elevance Health Inc.

    SCHEDULE 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    3/26/26 6:03:38 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Schulman Amy W

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/23/26 4:10:37 PM ET
    $ELV
    Medical Specialities
    Health Care

    EVP & President, Commercial Kendrick Charles Morgan Jr sold $910,604 worth of shares (3,196 units at $284.92), decreasing direct ownership by 21% to 11,791 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/9/26 4:45:08 PM ET
    $ELV
    Medical Specialities
    Health Care

    Director Collis Steven H bought $869,520 worth of shares (3,000 units at $289.84), increasing direct ownership by 469% to 3,639 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/6/26 8:03:27 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Collis Steven H bought $869,520 worth of shares (3,000 units at $289.84), increasing direct ownership by 469% to 3,639 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/6/26 8:03:27 AM ET
    $ELV
    Medical Specialities
    Health Care

    Director Devore Susan D. bought $374,580 worth of shares (1,200 units at $312.15), increasing direct ownership by 52% to 3,502 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    8/21/25 4:20:38 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $2,438,951 worth of shares (8,500 units at $286.94), increasing direct ownership by 6% to 151,020 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/18/25 1:42:51 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization

    Elevance Health, Inc. (NYSE:ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company's strategy to lower the cost of care. Carelon's operating priorities and client commitments remain unchanged. Felicia Norwood, Executive Vice President and Chief Health Benef

    2/26/26 3:02:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Appoints Nathan Rich Vice President, Investor Relations

    Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

    11/4/24 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Financials

    Live finance-specific insights

    View All

    Elevance Health Reports Fourth Quarter and Full Year 2025 Results; Sets Full Year 2026 Outlook

    4Q 2025 operating revenue of $49.3 billion; FY 2025 of $197.6 billion 4Q 2025 diluted EPS1 of $2.47; adjusted diluted EPS2 of $3.33 FY 2025 diluted EPS1 of $25.21; adjusted diluted EPS2 of $30.29 Projected FY 2026 GAAP diluted EPS1 to be at least $22.30 Projected FY 2026 adjusted diluted EPS2 to be at least $25.50 Returned $4.1 billion of capital to shareholders in 2025 Reaffirming long-term earnings algorithm; recalibrating segment margin targets Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2025 results. "Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined execution in a dynamic environment. As

    1/28/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2025 Results on January 28, 2026

    Elevance Health (NYSE:ELV) will release fourth quarter and full year 2025 financial results on January 28, 2026, at 6:00 a.m. Eastern Standard Time ("EST"). Management will review these results and its outlook during a conference call at 8:30 a.m. EST that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 888-566-0046 - No Access Code (Domestic Replay) 203-369-3677 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EST on January 28, 2026, until the end of the day on Februar

    12/22/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    AM Best Takes Various Credit Rating Actions on Elevance Health, Inc. and Most of Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) (NYSE:ELV), as well as most of its non-Blue-branded subsidiaries. In addition, AM Best has upgraded the FSR to A (Excellent) from A- (Excellent) and the Long-Term ICR to "a+" (Excellent) from "a-" (Excellent) of Wellpoint Life and Health Insurance Company and Wellpoint West Virginia, Inc. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of "bbb+"

    12/12/25 11:10:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

    SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    11/14/24 1:22:35 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/24 10:02:59 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/23 12:37:59 PM ET
    $ELV
    Medical Specialities
    Health Care